Tendon-fibrous cartilage-bone composite repair material based on bio-printing and application of tendon-fibrous cartilage-bone composite repair material

The tendon-fiber cartilage-bone composite repair material prepared through bioprinting technology solves the problem of scar formation of the tendon-bone interface regeneration tissue after rotator cuff injury, realizes gradient structure remodeling and functional reconstruction of the tendon-bone interface, and reduces refraction risk.

CN118976153AActive Publication Date: 2024-11-19BEIJING JISHUITAN HOSPITAL
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411074802.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-19
Estimated Expiration
2044-08-07

AI Technical Summary

Technical Problem

After the repair of rotator cuff injury, the regenerating tissue at the tendon bone interface is mostly scar-like, resulting in weakening of mechanical strength and increasing the risk of refractory after surgery. It is difficult for the existing technology to effectively restore the components, structure and mechanical gradient of the tendon bone interface, affecting the repair effect. .

Method used

Using bioprinted tendon-fibrous cartilage-bone composite repair material, the bone layer, fibrous cartilage layer and tendon layer are formed by printing the bioink composition, and using bone marrow mesenchymal stem cells, fibrous chondrocytes and tendon stem cells to combine the detachment. Calcium cancellous bone and extracellular matrix realizes gradient structure remodeling and regeneration of the tendon bone interface.

Benefits of technology

Improve the regeneration and repair effect of the tendon bone interface, enhance the energy metabolism level and biological behavior of cells, provide a tissue-specific microenvironment, promote long-term repair and functional reconstruction of the tendon bone interface, and reduce the rotator cuff injury after Risk of refraction of tendon.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976153A_ABST
    Figure CN118976153A_ABST
Patent Text Reader

Abstract

The invention provides a tendon-fibrous cartilage-bone composite repair material based on biological printing and application thereof, and relates to the technical field of tissue engineering. The composite repair material sequentially comprises a bone layer, a fibrous cartilage layer and a tendon layer from bottom to top, the bone layer is obtained by biological printing of a first biological ink composition containing bone marrow mesenchymal stem cells, decalcified cancellous bone and first biological ink; the fibrous cartilage layer is obtained by biological printing of a second biological ink composition containing fibrous cartilage cells, a fibrous cartilage extracellular matrix and second biological ink; the tendon layer is obtained by bio-printing a third bio-ink composition containing tendon stem cells, a tendon extracellular matrix and third bio-ink; the tendon stem cells and the bone marrow mesenchymal stem cells are pretreated by pioglitazone. The composite repair material relieves insufficient energy regulation in the early stage of rotator cuff injury repair, and can help remodeling of a gradient structure of a tendon-bone interface.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of tissue engineering, and in particular to a tendon-fibrocartilage-bone composite repair material based on bioprinting and application thereof. Background Art

[0002] The following statements merely provide background information related to the present disclosure and do not necessarily constitute prior art.

[0003] Rotator cuff injuries have a high incidence rate and are very harmful, seriously affecting the patient's quality of life and health. Rotator cuff injuries are common injuries caused by prolonged or high-intensity exercise. Currently, surgery is used clinically to reconstruct the anatomical position of the damaged tendon, but due to the poor healing effect of the tendon-bone interface, the re-rupture rate of the rotator cuff after repair surgery can be as high as 20% to 94%. Especially for huge and irreparable rotator cuff injuries, due to factors such as fat infiltration and progressive atrophy of the tendon-bone interface tissue, repair is extremely difficult. Therefore, the development of therapeutic products that can effectively repair the tendon-bone interface is a research hotspot in the field of sports medicine at home and abroad.

[0004] The tendon-bone interface is a "bridge" structure connecting tendons and bones. It includes tendons, non-mineralized fibrocartilage, mineralized fibrocartilage and bone tissue from shallow to deep. It is a special area with different components, structural compositions and mechanical properties. The four layers of tissue at the tendon-bone interface are gradient and intertwined. Its integrity can effectively reduce stress concentration and transfer the force from tendons to bones, thereby reducing the risk of tendon rupture and fracture.

[0005] Although traditional surgery and fixation methods can restore the continuity of the tendon-bone interface in clinical practice, the regenerated tissue is mostly scar-based, which leads to weakened mechanical strength and increased risk of re-rupture after surgery. Ideal tendon-bone interface reconstruction requires, on the one hand, the restoration of the spatial heterogeneity of the components, structures, and mechanics of each tissue, including good regeneration and gradual transition of tendons, fibrocartilage, and bone tissues; on the other hand, it requires a high repair timeliness and needs to provide a good "regeneration microenvironment" for the tendon-bone interface in a timely manner. Therefore, initiating tendon-bone interface repair as early as possible and restoring the spatial gradient structure of the tendon-bone interface at the same time can achieve good functional reconstruction in order to reduce the occurrence of tendon re-rupture after rotator cuff repair. Therefore, reconstructing the transitional gradient structure of the tendon-bone interface and providing a good "regeneration microenvironment" for the healing of the tendon-bone interface as early as possible has always been the focus of research on rotator cuff injury repair.

[0006] In view of this, the present invention is proposed. Summary of the invention

[0007] The purpose of the present invention is to provide a tendon-fibrocartilage-bone composite repair material based on bioprinting to alleviate the insufficient energy regulation in the early stage of rotator cuff injury repair and help reshape the gradient structure of the tendon-bone interface.

[0008] In order to solve the above technical problems, the present invention particularly adopts the following technical solutions:

[0009] In a first aspect, a tendon-fibrocartilage-bone composite repair material based on bioprinting is provided, wherein the composite repair material comprises a bone layer, a fibrocartilage layer and a tendon layer in order from bottom to top;

[0010] The bone layer is obtained by bio-printing a first bio-ink composition, wherein the first bio-ink composition comprises bone marrow mesenchymal stem cells, decalcified cancellous bone and a first bio-ink;

[0011] The fibrocartilage layer is obtained by bioprinting a second bio-ink composition, wherein the second bio-ink composition comprises fibrocartilage cells, fibrocartilage extracellular matrix, and a second bio-ink;

[0012] The tendon layer is obtained by bioprinting a third bio-ink composition, wherein the third bio-ink composition comprises tendon stem cells, tendon extracellular matrix and a third bio-ink;

[0013] The tendon stem cells and the bone marrow mesenchymal stem cells are pretreated with pioglitazone.

[0014] In a second aspect, a set of bio-ink compositions is also provided, the set of bio-ink compositions comprising the first bio-ink composition of the first aspect, the second bio-ink composition of the first aspect, and the third bio-ink composition of the first aspect, which are separately packaged.

[0015] In a third aspect, a method for preparing the tendon-fibrocartilage-bone composite repair material based on bioprinting of the first aspect is also provided, the preparation method comprising using a bioprinting device to print the first bio-ink composition, the second bio-ink composition and the third bio-ink composition to form a composite repair material comprising the bone layer, the fibrocartilage layer and the tendon layer.

[0016] In a fourth aspect, there is provided the use of the tendon-fibrocartilage-bone composite repair material of the first aspect, the biological ink of the second aspect, or the preparation method of the third aspect in the preparation of a product for repairing rotator cuff injuries.

[0017] In a fifth aspect, a product for repairing rotator cuff injury is also provided, comprising the tendon-fibrocartilage-bone composite repair material of the first aspect or the set of biological ink of the second aspect.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] (1) The tendon stem cells and bone marrow mesenchymal stem cells in the composite repair material provided by the present invention are pretreated with pioglitazone, which enhances the mitochondrial production of these cells and improves the efficiency of mitochondrial delivery between cells. In vitro, it is confirmed that the indirect delivery of mitochondria by engineered stem cells regulates the energy metabolism level of related damaged cells (increase in ATP and MtDNA content) and enhances their biological behavior (increase in cell proliferation ability), thereby achieving energy metabolism reprogramming of damaged tissues / cells.

[0020] (2) The decalcified cancellous bone, fibrocartilage extracellular matrix and tendon extracellular matrix in the composite repair material provided by the present invention all have good biocompatibility, degradability and biomechanical properties, can provide a tissue-specific microenvironment for cell growth, provide chemical signals and biomechanical signals, induce and regulate cell adhesion, growth, proliferation and differentiation, and promote tissue repair and regeneration without degradation and removal.

[0021] (3) The composite repair material uses multicellular bioprinting technology to achieve the integrated construction of three bio-ink compositions in three regions (tendon region, fibrocartilage region, and bone region) to improve the regeneration and repair effect of the tendon-bone interface tissue after rotator cuff injury.

[0022] (4) This composite repair material not only effectively solves the shortcomings of low efficiency and short-term high efficiency of direct mitochondrial delivery, and can slowly release mitochondria over a long period of time, but also can reproduce the composition, structure and cell-mimicking tendon-bone interface tissue structure, thereby better repairing rotator cuff injuries. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0024] Figure 1 This is a design diagram for the study of Example 1;

[0025] Figure 2 This is a photo of the composite repair material prepared in Example 1;

[0026] Figure 3 The dead cell and live cell staining results (A) and the semi-quantitative analysis results of cell survival rate (B) after the cells were treated with the extract of the composite repair material prepared in Example 1;

[0027] Figure 4The staining results of dead cells and living cells and the adhesion morphology in the bone layer of the composite repair material prepared in Example 1, A is the staining result of living cells, B is the staining result of dead cells, C is the adhesion and morphology results, Bar=50μm;

[0028] Figure 5 ATP level (A), mtDNA content (B), and proliferation capacity (C) of fibrochondrocytes co-cultured with Pg-TSPCs and Pg-BMSCs;

[0029] Figure 6 The results of in vivo histology H&E staining and Safranin O / Fast Green of the implanted groups in each experimental group at 6 weeks, Bar=500 μm. DETAILED DESCRIPTION

[0030] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] In a first aspect, a tendon-fibrocartilage-bone composite repair material based on bioprinting is provided, wherein the composite repair material comprises a bone layer, a fibrocartilage layer and a tendon layer from bottom to top.

[0032] The bone layer is obtained by bio-printing a first bio-ink composition, wherein the first bio-ink composition comprises bone marrow mesenchymal stem cells, decalcified cancellous bone and a first bio-ink.

[0033] In an optional embodiment, the content of bone marrow mesenchymal stem cells in the first bio-ink composition is 1 to 10×10 5 / mL, for example, can be but not limited to 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10×10 5 / mL; the content of decalcified cancellous bone is 1-5%wt, for example, but not limited to 1, 2, 3, 4 or 5%wt.

[0034] In an optional embodiment, the content of bone marrow mesenchymal stem cells in the first bio-ink composition is 3×10 5 / mL, and the content of decalcified cancellous bone was 2%wt.

[0035] The bone marrow mesenchymal stem cells in the first bio-ink composition are pretreated with pioglitazone.

[0036] In an optional embodiment, the pretreatment of the bone marrow mesenchymal stem cells with pioglitazone comprises culturing the bone marrow mesenchymal stem cells with a culture medium containing pioglitazone;

[0037] In an optional embodiment, the concentration of pioglitazone in the culture medium for pretreating bone marrow mesenchymal stem cells is 5-20 μM, for example, but not limited to 5, 10, 15 or 20 μM, preferably 10 μM.

[0038] In an optional embodiment, the culture time of bone marrow mesenchymal stem cells in the medium containing pioglitazone is 100 to 140 hours, for example, but not limited to 100, 110, 120, 130 or 140 hours, preferably 120 hours.

[0039] The fibrocartilage layer is obtained by bioprinting a second bio-ink composition, wherein the second bio-ink composition comprises fibrocartilage cells, fibrocartilage extracellular matrix and a second bio-ink.

[0040] In an optional embodiment, the content of fibrochondrocytes in the second bio-ink composition is 1 to 10×10 5 / mL, for example, can be but not limited to 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10×10 5 / mL; the content of fibrocartilage extracellular matrix is ​​1-5%wt, for example, but not limited to 1, 2, 3, 4 or 5%wt.

[0041] In an optional embodiment, the content of fibrochondrocytes in the second bio-ink composition is 3×10 5 / mL, and the content of fibrocartilage extracellular matrix was 2%wt.

[0042] The tendon layer is obtained by bio-printing a third bio-ink composition, wherein the third bio-ink composition comprises tendon stem cells, tendon extracellular matrix and a third bio-ink.

[0043] In an optional embodiment, the content of tendon stem cells in the third bio-ink composition is 1 to 10×10 5 / mL, for example, can be but not limited to 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10×10 5 / mL; the content of tendon extracellular matrix is ​​1-5%wt, for example, but not limited to 1, 2, 3, 4 or 5%wt.

[0044] In an optional embodiment, the content of tendon stem cells in the third bio-ink composition is 3×10 5 / mL, and the content of tendon extracellular matrix was 2%wt.

[0045] The tendon stem cells in the third bio-ink composition are pretreated with pioglitazone.

[0046] In an optional embodiment, the pretreatment of the tendon stem cells with pioglitazone comprises culturing the tendon stem cells using a culture medium containing pioglitazone;

[0047] In an optional embodiment, the concentration of pioglitazone in the culture medium for pre-treating tendon stem cells is 5-20 μM, for example, but not limited to 5, 10, 15 or 20 μM, preferably 10 μM.

[0048] In an optional embodiment, the culture time of tendon stem cells using a culture medium containing pioglitazone is 100 to 140 hours, for example, but not limited to 100, 110, 120, 130 or 140 hours, preferably 120 hours.

[0049] In an optional embodiment, the first bio-ink, the second bio-ink and the third bio-ink each independently include a hydrogel. The hydrogel compositions constituting the first bio-ink, the second bio-ink and the third bio-ink may be the same or different. The hydrogel may include any hydrogel known in the art that can be used as a bio-ink, including but not limited to one or more of alginate, gelatin, chitosan, silk fibroin, fibrinogen, hyaluronic acid, cellulose, polyethylene glycol, polyglycolic acid, polylactic acid and polylactic acid-polyglycolic acid.

[0050] In an optional embodiment, the first bio-ink includes a photocurable hydrogel, preferably a GelMa (methacrylic anhydride gelatin) hydrogel. In an optional embodiment, the first bio-ink is a GelMa hydrogel with a concentration of 2 to 10% wt (for example, but not limited to 2, 3, 4, 5, 6, 7, 8, 9 or 10% wt), preferably a GelMa hydrogel with a concentration of 5% wt. Optionally, the first bio-ink also contains a photoinitiator.

[0051] In an optional embodiment, the second bio-ink includes a photocurable hydrogel, preferably a GelMa hydrogel. In an optional embodiment, the second bio-ink is a GelMa hydrogel with a concentration of 2 to 10% wt (for example, but not limited to 2, 3, 4, 5, 6, 7, 8, 9 or 10% wt), preferably a GelMa hydrogel with a concentration of 5% wt. Optionally, the second bio-ink also contains a photoinitiator.

[0052] In an optional embodiment, the third bio-ink includes a photocurable hydrogel, preferably a GelMa hydrogel. In an optional embodiment, the third bio-ink is a GelMa hydrogel with a concentration of 2 to 10% wt (for example, but not limited to 2, 3, 4, 5, 6, 7, 8, 9 or 10% wt), preferably a GelMa hydrogel with a concentration of 5% wt. Optionally, the third bio-ink also contains a photoinitiator.

[0053] In an optional embodiment, the photoinitiator includes LAP (lithium phenyl-2,4,6-trimethylbenzoylphosphinate).

[0054] In an optional embodiment, a light-curing bioprinting device is used for layer-by-layer 3D printing, and the printing parameters include: light intensity 5-10mw / cm 2 , exposure time 10 to 15 seconds, number of base layers 5 to 10 and base layer exposure time 8 to 12 seconds.

[0055] In an optional embodiment, the printing parameters include: light intensity 8mw / cm 2 , exposure time 12s, number of base layers 6 and base layer exposure time 10s.

[0056] The demineralized cancellous bone (DCB) and decellularized extracellular matrix (dECM) in the bioprinting-based tendon-fibrocartilage-bone composite repair material provided in the first aspect are excellent biomaterials for tissue regeneration. The fibrocartilage extracellular matrix (FCECM) of decellularized cartilage and the tendon extracellular matrix (TECM) of detenocytes have good biocompatibility and can promote the proliferation and chondrogenic / tendon differentiation of stem cells (MSCs). DCB is one of the bio-derived scaffold materials, which mainly utilizes homologous or xenogeneic organs / tissues, and obtains decellularized matrix materials after decellularization and antigen removal. The material has an extracellular matrix component and contains type I collagen. Collagen is a good scaffold for cell adhesion and growth, and is a good biogenic material for bone repair.

[0057] To mimic natural tissue, the chemical and mechanical properties of 3D tissue constructs should mimic the characteristics of natural tissue. Gradients of cell types, biomolecules, and other structural and compositional components also need to be developed in certain types of bioprinted tissue constructs. To meet these needs, the shape, flow, and composition of cell-laden fibers need to be precisely controlled during the bioprinting process. Therefore, methods that can more precisely control the organization of materials, cells, and biomolecules in the resulting 3D structures are needed to accurately mimic the composition of natural tissues. Bioprinting helps to adjust the structural and compositional properties of tissue constructs during the printing process. 3D bioprinting systems can be used to control cell and molecular deposition, flow, mixing, and gradient construction in the final 3D structure to complete the reconstruction of transitional complex tendon-bone interface tissues.

[0058] The delivery of normally functioning mitochondria into damaged tissue cells to supplement dysfunctional mitochondria and achieve the remodeling of energy metabolism is called mitochondrial replenishment therapy (MRT). The use of cells as carriers to deliver mitochondria can avoid the risk of additional mitochondrial separation, transfer, and loss of activity. Suitable carrier cells should meet the requirements of targeted migration to damaged tissues, spontaneous mitochondrial delivery, strong mitochondrial generation capacity, and low energy requirements. Mesenchymal stem cells (MSCs) have low bioenergy requirements in the glycolytic state, which is the basis for their delivery of their own mitochondria to damaged tissue cells. Human placenta-derived mesenchymal stem cells (hMSCs) treated with pioglitazone (PG) can activate the continuous production of mitochondria in hMSCs by activating the PGC-1a-NRF1-TFAM pathway, and can promote mitochondrial transfer between cells to a certain extent. Therefore, the introduction of mesenchymal stem cells (MSCs) treated with PG into damaged tissues can promote the healing of tissues, especially the tendon-bone interface after rotator cuff injury.

[0059] 3D bioprinting can achieve precise positional control of cells and extracellular matrix components, and further create complex and functional multicellular tissues or organs in a 3D environment, which is conducive to the application of scaffold-based or scaffold-free tissue and organ structures, microorganisms, and single-chip organ model systems. 3D bioprinting uses inkjet, extrusion, and laser-based methods to create geometrically complex and scalable tissues. As an emerging technology, 3D bioprinting can construct complex soft and hard tissue structures by gradually depositing seed cells, metal ions, growth factors, and other biomaterials, thereby simulating the structure, cells, and composition characteristics of the tendon-bone interface.

[0060] 3D bioprinting also has the potential to repeatedly develop 3D structured tissues through controlled and optimized microenvironments, where intrinsic cellular morphology and architecture can be reconstructed. Higher-order assembly of multicellular bioprinted structures can be developed through organized spatial patterns and tissue-specific gene expression. In addition, 3D bioprinting offers the potential to fabricate multicellular complex tissue structures by sequentially depositing different cell types, different active molecules, and biomaterials located in specific areas.

[0061] The tendon-fibrocartilage-bone composite repair material based on bioprinting provided in the first aspect is designed by multicellular bioprinting technology based on the good biocompatibility and differentiation-promoting effect of the extracellular matrix material, and a composite repair material composed of three biological ink components is designed. It can be regulated and mixed, and on the basis of bone, fibrocartilage and tendon extracellular matrix biological ink, a tissue-derived biological ink composition containing bone marrow mesenchymal stem cells (PG pretreatment), fibrocartilage cells and tendon stem cells (PG pretreatment) is printed from bottom to top. In the preferred scheme, the composite repair material can take into account the gradual seed cells, extracellular components and structural characteristics, can effectively reconstruct the tendon area, fibrocartilage area and bone area, and deliver mitochondria to the damaged part cells through pg-MSCs, and reprogram the energy metabolism of the damaged part. Promote the good reconstruction of the tendon-bone interface after rotator cuff injury from the perspectives of space and time.

[0062] In the second aspect, a complete set of bio-ink compositions is also provided, the complete set of bio-ink compositions comprising the first bio-ink composition in the first aspect, the second bio-ink composition in the first aspect, and the third bio-ink composition in the first aspect, which are separately packaged. The complete set of bio-ink compositions can construct the tendon-fibrocartilage-bone composite repair material based on bioprinting in the first aspect.

[0063] In an optional embodiment, the content of bone marrow mesenchymal stem cells in the first bio-ink composition is 1 to 10×10 5 / mL, the content of decalcified cancellous bone is 1 to 5%wt; the content of fibrochondrocytes in the second bio-ink composition is 1 to 10×10 5 / mL, the content of fibrocartilage extracellular matrix is ​​1 to 5%wt; and the content of tendon stem cells in the third bio-ink composition is 1 to 10×10 5 / mL, and the content of tendon extracellular matrix is ​​1-5%wt.

[0064] In an optional embodiment, the content of bone marrow mesenchymal stem cells in the first bio-ink composition is 3×10 5 / mL, the content of decalcified cancellous bone is 2%wt; the content of fibrochondrocytes in the second bio-ink composition is 3×10 5 / mL, the content of fibrocartilage extracellular matrix is ​​2%wt; and the content of tendon stem cells in the third bio-ink composition is 3×10 5 / mL, and the content of tendon extracellular matrix was 2%wt.

[0065] In an optional embodiment, the bone marrow mesenchymal stem cells in the first bio-ink composition are bone marrow mesenchymal stem cells cultured in a culture medium containing 5 to 20 μM pioglitazone for 100 to 140 hours, preferably bone marrow mesenchymal stem cells cultured in a culture medium containing 10 μM pioglitazone for 120 hours.

[0066] In an optional embodiment, the tendon stem cells in the third bio-ink composition are tendon stem cells cultured in a culture medium containing 5 to 20 μM pioglitazone for 100 to 140 hours, preferably tendon stem cells cultured in a culture medium containing 10 μM pioglitazone for 120 hours.

[0067] In an optional embodiment, the first bio-ink, the second bio-ink and the third bio-ink include photocured hydrogels, preferably GelMa.

[0068] In an optional embodiment, the first bio-ink composition, the second bio-ink composition and the third bio-ink composition further contain a photoinitiator, and the photoinitiator preferably includes LAP.

[0069] In a third aspect, a method for preparing the tendon-fibrocartilage-bone composite repair material based on bioprinting of the first aspect is also provided, the preparation method comprising using a bioprinting device to print the first bio-ink composition, the second bio-ink composition and the third bio-ink composition to form a composite repair material comprising the bone layer, the fibrocartilage layer and the tendon layer.

[0070] In an optional embodiment, a light-curing bioprinting device is used for layer-by-layer 3D printing, and the printing parameters include: light intensity 5-10mw / cm 2 , exposure time 10 to 15 seconds, number of base layers 5 to 10 and base layer exposure time 8 to 12 seconds.

[0071] In an optional embodiment, the printing parameters include: light intensity 8mw / cm 2 , exposure time 12s, number of base layers 6 and base layer exposure time 10s.

[0072] In a fourth aspect, there is provided the use of the tendon-fibrocartilage-bone composite repair material of the first aspect, the set of biological ink of the second aspect, or the preparation method of the third aspect in the preparation of a product for repairing rotator cuff injuries.

[0073] In a fifth aspect, a product for repairing rotator cuff injury is also provided, which comprises the tendon-fibrocartilage-bone composite repair material described in the first aspect or the set of biological ink described in the second aspect.

[0074] In an optional embodiment, the rotator cuff injury repair product includes the tendon-fibrocartilage-bone composite repair material of the first aspect, and optionally includes a pharmaceutical component for alleviating or treating rotator cuff injuries that is optional in the art.

[0075] In an optional embodiment, the rotator cuff injury repair product includes the complete set of biological inks described in the second aspect. When used, the complete set of biological inks is printed according to the shape of the graft required for the affected area to obtain the corresponding rotator cuff injury composite repair material.

[0076] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.

[0077] Example 1

[0078] This embodiment provides a tendon-fibrocartilage-bone composite repair material based on bioprinting, and the research design diagram is as follows Figure 1 shown.

[0079] 1. Preparation of engineered MSCs:

[0080] (1) Tendon stem cells (TSPCs) were seeded and cultured overnight, and then co-cultured with 10 μM Pg (pioglitazone) solution for 5 days to obtain Pg-TSPCs (engineered tendon stem cells).

[0081] (2) Bone marrow mesenchymal stem cells (BMSCs) were seeded and cultured overnight, and then co-cultured with 10 μM Pg (pioglitazone) solution for 5 days to obtain Pg-BMSCs (engineered bone marrow mesenchymal stem cells).

[0082] (3) Fibrochondrocytes: Take the meniscus tissue of the rat knee joint and cut the inner 2 / 3 area of ​​the meniscus in a sterile culture dish. Wash it with PBS three times and cut the meniscus into 1 mm pieces with sterile ophthalmic scissors. 3 The tissue fragments were removed and then 0.2% type 2 collagenase was added. The tissue fragments were placed in a 37°C, 5% CO2 incubator and digested for 60 min with the help of a magnetic stirrer until the tissue fragments disappeared. The digestion was terminated by adding DMEM culture medium containing 10% FBS and the tissue was cultured to the 2nd to 3rd generation for later use.

[0083] 2. Preparation of decalcified cancellous bone (DCB):

[0084] Fresh pig scapula was used, and the periosteum, cartilage and soft tissue were removed. The cancellous bone was taken and prepared into a round cake shape. The bone marrow, blood stains and surface grease were removed by repeated washing with running water and stirring. After washing with tap water, the bone marrow, blood stains and surface grease were removed. After washing with tap water, the bone marrow was stored at -80℃ for 3 days, and then the following steps were carried out in sequence:

[0085] (1) Dehydrate with anhydrous ethanol for 2 h and air dry;

[0086] (2) Chloroform / methanol 1:1, volume fraction, degrease for 4 h, air-dry;

[0087] (3) decalcification with 0.6 mol / L hydrochloric acid for 6 h, hydrochloric acid / cancellous bone: 20 ml / g, air-dried;

[0088] (4) dehydrate with anhydrous ethanol for 2 h and air dry;

[0089] (5) Chloroform / methanol 1:1, volume fraction, degrease for 4 h, air-dry;

[0090] (6) 10% PBS, pH = 7.4, soak at 37°C for 3 days, change the solution twice, air-dry and grind into powder for later use.

[0091] 3. Preparation of fibrocartilage extracellular matrix (FCECM) and tendon extracellular matrix (TECM):

[0092] (1) Take fresh pig meniscus and rinse it three times with phosphate buffered saline (PBS, pH 7.4);

[0093] (2) Immerse the fibrocartilage in EOW (acidic oxidative potential water) for initial sterilization three times, 10 minutes each time;

[0094] (3) Aseptically cut the cartilage into small pieces of about 1 mm using ophthalmic scissors and rinse them three times with sterile distilled water;

[0095] (4) Soak in 3% hydrogen peroxide for 30 min and rinse with sterile distilled water three times, 30 min each time;

[0096] (5) Put it into a grinder and crush it, add 2 times sterile triple-distilled water and repeatedly grind the cartilage homogenate at low temperature;

[0097] (6) Add 10 times triple distilled water and mix hypotonicly. Freeze the hypotonic cell homogenate at -20°C and thaw at room temperature for 4 freeze-thaw cycles.

[0098] (7) Gradient centrifugation: centrifuge the crushed homogenate at 2000 rpm for 30 minutes to obtain the supernatant;

[0099] (8) Centrifuge at 3000 rpm for 30 minutes and collect the supernatant;

[0100] (9) Centrifuge at 4000 rpm for 30 min, take the supernatant, repeat 5 times to thoroughly wash away cell debris and residual substances, and wash to pH 7.0;

[0101] (10) The upper layer was homogenized at 10,000 rpm and centrifuged at 4°C for 30 min. The supernatant was removed and the precipitate was collected as a cell-free nano-ECM slurry. After freeze-drying, it was ground into powder for later use.

[0102] The method for preparing the tendon extracellular matrix is ​​the same as the above-mentioned fibrocartilage extracellular matrix. The tendon tissue is processed by the above-mentioned steps to obtain the tendon extracellular matrix.

[0103] 4. Preparation of Bio-ink Composition:

[0104] (1) Bone layer bio-ink (first bio-ink composition): containing engineered bone marrow mesenchymal stem cells (3×10 5 / mL) and DCB (2% wt) in GelMa hydrogel (5% GelMa, 0.25 g / LLAP).

[0105] (2) Fibrocartilage layer bio-ink (second bio-ink composition): containing fibrocartilage cells (3×10 5 / mL) and FCECM (2% wt) in GelMa hydrogel (5% GelMa, 0.25 g / L LAP).

[0106] (3) Tendon layer bio-ink (third bio-ink composition): containing engineered tendon stem cells (3×10 5 / mL) and TECM (2% wt) in GelMa hydrogel (5% GelMa, 0.25 g / L LAP).

[0107] 5. Preparation of gradient bioprinting hydrogels:

[0108] Use photocurable 3D bioprinting technology, printing parameters: DLP (digital light processing) technology is used to 3D print the scaffold layer by layer through a photocurable printer, and the bone layer bio-ink, fibrocartilage layer bio-ink and tendon layer bio-ink prepared in the previous step are added to the 3D printer material cup respectively, and the parameter light intensity is set to 8mw / cm 2 ; Exposure time 12s; Number of base layers 6 base layers exposure time 10s, and successfully printed at room temperature, realizing the simultaneous mixed printing of three bio-inks in the tendon-fibrocartilage-bone integrated scaffold and the tendon layer and bone layer containing mitochondrial engineered MSCs, and finally achieving multi-cellular bioprinting in the tendon area, fibrocartilage area and bone area. The photo of the composite repair material obtained in this example is shown in Figure 2 shown.

[0109] 6. Effect verification:

[0110] (1) The cells were cultured with the extract of the composite hydrogel repair material prepared in the above steps for 1, 3, and 7 days, and the biocompatibility of the repair material was observed by dead / live cell staining. Specifically, the fibrochondrocytes cultured in a 6-well plate were immersed in 2 mL PBS working solution containing 4 mM homodimer-1 and 2 mM calcein-AM for 30 min. The fluorescence microscope was used to select excitation wavelengths of 556 nm and 488 nm to detect the imaging of ethidium homodimer-1 (red represents dead cells) and calcein-AM (green represents live cells). The staining results and semi-quantitative analysis results of cell viability are shown in Figure 2. Figure 3 As shown, it can be seen that there is no significant difference between the extract of the composite repair material and the control group, indicating that it is not cytotoxic and does not affect the survival rate of cells. The composite repair material is safe.

[0111] (2) Further, fibrochondrocytes were cultured in the composite repair material prepared in the above steps, and dead / live cell staining and cytoskeleton staining were performed. Specifically, after 1 day of culture, 4',6-diamidino-2-phenylindole (DAPI) and phalloidin (Cytoskeleton, USA) were used to further evaluate the morphology of fibrochondrocytes on the repair material. The dead / live staining results and cytoskeleton staining results are shown in Figure 2. Figure 4 As shown, from Figure 4 It can be seen that the printing process does not harm the survival of cells in the bio-ink composition, and the cell activity in the prepared composite repair material is good.

[0112] (3) Pg-TSPCs and Pg-BMSCs were cultured in the upper layer of the Transwell chamber, and fibrochondrocytes stimulated by IL-1β were placed in the lower layer of the chamber for co-culture with the engineered stem cells. ATP levels and mtDNA content were detected after 7 days of co-culture. The results are as follows Figure 5 As shown in A and B, the ATP level and mtDNA content in the Pg-TSPCs and Pg-BMSCs groups were significantly increased compared with the damaged control group. This finding was associated with the number of transferred mitochondria, indicating that the mitochondrial energy metabolism of damaged fibrochondrocytes was upregulated. Furthermore, the engineered stem cells were co-cultured with fibrochondrocytes for 1, 3, 5, and 7 days and the proliferation capacity after culture was detected using CCK-8 reagent. The results showed that the cell proliferation capacity of the Pg-TSPCs and Pg-BMSCs groups was significantly increased compared with the control group.

[0113] (4) The composite repair material prepared in the above steps was implanted into a rat rotator cuff injury model. The animal operation was as follows: the rat was anesthetized, and the skin around the left shoulder joint was prepared and partially disinfected. The deltoid muscle was surgically exposed, separated and incised, and the supraspinatus muscle was exposed. The supraspinatus muscle was separated and the tendon was cut at the junction of the supraspinatus tendon and the humerus. The supraspinatus muscle was re-sutured to the greater tuberosity. In the composite material implantation group, the material was directly transplanted into the gap between the tendon and the bone interface. The wound tissue layers were closed layer by layer to complete the rotator cuff injury repair model.

[0114] The experimental groups are as follows:

[0115] Number of groups Group quantity 1 Sham operation group 4 2 Simple gel group (control) 4 3 Engineered stem cell gel group 4

[0116] In vivo histological staining results Figure 6 As shown in the figure, H&E and Safranin O / Fast Green staining were used to evaluate the histology of the regenerated tissue. The collagen fibers in the fibrocartilage area of ​​the sham group were neatly arranged. At 6 weeks after surgery, H&E staining showed that the repaired tendon in the control group had not yet healed, with a large number of inflammatory cells infiltrating, almost no fibrocartilage cells, hypervascularization, discontinuous collagen fibers, and its morphology was consistent with the state of scar tissue: loose and irregular arrangement. In the experimental group, there was less inflammatory cell infiltration in the repair area, an increase in fibrocartilage-like cells, and neat arrangement of collagen fibers. At week 12, the repair process was completed, and almost no inflammatory cells were found in each group. Some fibrocartilage-like cells and regenerated fibrocartilage tissue were visible in the control group, and the collagen fibers were arranged relatively orderly. The fibrocartilage tissue in the experimental group was wider, the tendon-bone interface was obvious, and the anatomical structure was closer to the sham group. Safranin O / Fast Green staining was used to evaluate the polysaccharide deposition at the tendon-bone interface; at 6 weeks, there was only a small amount of scattered polysaccharide in the control group, while the polysaccharide deposition was good in the experimental group at 6 weeks. At 12 weeks, uneven staining was still visible in the control group, while a large amount of polysaccharide was visible in the experimental group. This indicates that the composite repair material prepared in this example can effectively promote the healing of the tendon-bone interface after rotator cuff injury.

[0117] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A tendon-fibrocartilage-bone composite repair material based on bioprinting, characterized in that: From bottom to top, it includes the bone layer, fibrocartilage layer and tendon layer; The bone layer is obtained by bio-printing a first bio-ink composition, wherein the first bio-ink composition comprises bone marrow mesenchymal stem cells, decalcified cancellous bone and a first bio-ink; The fibrocartilage layer is obtained by bioprinting a second bio-ink composition, wherein the second bio-ink composition comprises fibrocartilage cells, fibrocartilage extracellular matrix, and a second bio-ink; The tendon layer is obtained by bioprinting a third bio-ink composition, wherein the third bio-ink composition comprises tendon stem cells, tendon extracellular matrix and a third bio-ink; The tendon stem cells and the bone marrow mesenchymal stem cells are pretreated with pioglitazone.

2. The composite repair material according to claim 1, characterized in that: The content of bone marrow mesenchymal stem cells in the first bio-ink composition is 1 to 10×10 5 / mL, the content of decalcified cancellous bone is 1-5%wt; Optionally, the content of fibrochondrocytes in the second bio-ink composition is 1 to 10×10 5 / mL, the content of fibrocartilage extracellular matrix is ​​1-5%wt; Optionally, the content of tendon stem cells in the third bio-ink composition is 1 to 10×10 5 / mL, and the content of tendon extracellular matrix is ​​1-5%wt.

3. The composite repair material according to claim 2, characterized in that: The content of bone marrow mesenchymal stem cells in the first bio-ink composition is 3×10 5 / mL, the content of decalcified cancellous bone was 2%wt; Optionally, the content of fibrochondrocytes in the second bio-ink composition is 3×10 5 / mL, the content of fibrocartilage extracellular matrix was 2%wt; Optionally, the content of tendon stem cells in the third bio-ink composition is 3×10 5 / mL, and the content of tendon extracellular matrix was 2%wt.

4. The composite repair material according to claim 1, characterized in that: The pioglitazone pretreatment of tendon stem cells includes culturing the tendon stem cells using a medium containing pioglitazone; and / or, the pretreatment of the bone marrow mesenchymal stem cells with pioglitazone comprises culturing the bone marrow mesenchymal stem cells with a medium containing pioglitazone; Optionally, in the culture medium containing pioglitazone, the concentration of pioglitazone is 5 to 20 μM, preferably 10 μM; Optionally, the culture time is 100 to 140 hours, preferably 120 hours.

5. The composite repair material according to claim 1, characterized in that: The first bio-ink, the second bio-ink and the third bio-ink each independently comprise a hydrogel; Optionally, the hydrogel comprises one or more of alginate, gelatin, chitosan, silk fibroin, fibrinogen, hyaluronic acid, cellulose, polyethylene glycol, polyglycolic acid, polylactic acid, and polylactic-polyglycolic acid; Optionally, the hydrogel comprises a photocured hydrogel; Optionally, the hydrogel comprises GelMa hydrogel; Optionally, the first bio-ink, the second bio-ink and the third bio-ink are each independently a GelMa hydrogel with a concentration of 2 to 10% wt, preferably a GelMa hydrogel with a concentration of 5% wt. Optionally, the first bio-ink, the second bio-ink and the third bio-ink each independently contain a photoinitiator.

6. The composite repair material according to any one of claims 1 to 5, characterized in that: Use a light-curing bioprinting device for layer-by-layer 3D printing. The printing parameters include: light intensity 5-10mw / cm 2 , exposure time 10-15s, number of base layers 5-10 and base layer exposure 8-12s; Optionally, printing parameters include: light intensity 8mw / cm 2 , exposure time 12s, number of base layers 6 and base layer exposure time 10s.

7. A complete set of biological ink compositions, characterized in that: The invention comprises the first bio-ink composition according to any one of claims 1 to 6, the second bio-ink composition according to any one of claims 1 to 6, and the third bio-ink composition according to any one of claims 1 to 6, which are separately packaged.

8. The method for preparing the tendon-fibrocartilage-bone composite repair material based on bioprinting according to any one of claims 1 to 6, characterized in that: The method comprises printing the first bio-ink composition, the second bio-ink composition and the third bio-ink composition using a bio-printing device to form a composite repair material comprising the bone layer, the fibrocartilage layer and the tendon layer.

9. Use of the tendon-fibrocartilage-bone composite repair material according to any one of claims 1 to 6, the set of biological ink according to claim 7, or the preparation method according to claim 8 in the preparation of products for repairing rotator cuff injuries.

10. A product for repairing rotator cuff injury, characterized in that: The invention comprises the tendon-fibrocartilage-bone composite repair material according to any one of claims 1 to 6 or the complete set of biological ink according to claim 7.

Citation Information

Patent Citations

  • Tendon-bone combined three-phase scaffold prepared by fusion electrospinning three-dimensional printing

    CN109837215A

  • 3D bionic biological scaffold containing stem cell exosomes and application

    CN113398332A

  • Bio-printing tendon-like-bone multicellular scaffold as well as preparation method and application thereof

    CN115944776A

  • Stimulating platelet generation by activating mitochondrial biogenesis

    US20200030353A1

  • Injectable off-the- shelf cartilage, tendon, and ligament repair compositions and methods of use

    US20210047612A1